The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Produktform

1mg/ml in PBSwith0.1%SodiumAzide,50%Glycerol.

Synonyme

C1 esterase inhibitor, C1 Inactivator, C1 Inh, C1 inhibiting factor, C1 inhibitor, C1-inhibiting factor, C1IN, C1Inh, C1NH, complement component 1 inhibitor, esterase inhibitor, HAE1, HAE2, IC1_HUMAN, Plasma protease C1 inhibitor, Serine (or cysteine) proteinase inhibitor clade G member 1, serine/cysteine proteinase inhibitor clade G member 1, Serpin G1, serpin peptidase inhibitor, clade G (C1 inhibitor), member 1

Kompatible Sekundärantikörper

Haftungsausschluss

Dieses Produkt ist nur für Forschungszwecke bestimmt. Es ist nicht für diagnostische oder therapeutische Zwecke bestimmt.

Produktbilder (1)

Bild Vergrößern

Figure 1: Anti-SERPING1 Antibody (BS6540)

For details please refer to datasheet.

Produktreferenzen (1)

Publikation anzeigen

Apocynin improves erectile function in diabetic rats through regulation of NADPH oxidase expression.

Verweise: Anti-SERPING1 Antibody (A29794)

Abstrakt:

INTRODUCTION:

Diabetes is a risk factor for erectile dysfunction (ED). The proposed mechanisms responsible for diabetic ED are associated with an increase in reactive oxygen species (ROS) production, overactivity of RhoA/ROCK signaling pathway and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, as seen in experimental models of diabetic rats.

AIM:

The aim of this study was to investigate whether NADPH oxidase inhibitor apocynin can ameliorate Streptozotocin (STZ)-induced diabetes-related ED by reducing the ROS production and inhibiting the activity of RhoA/ROCK signaling pathway.

METHODS:

The diabetic rats were treated with and without the NADPH oxidase inhibitor apocynin.

MAIN OUTCOME MEASURES:

Erectile responses were evaluated by determining mean arterial blood pressure (MAP) and intracavernosal pressure (ICP) with electrical stimulation of the cavernous nerve. Levels of mRNA expression were measured by real-time polymerase chain reaction (RT-PCR). Levels of protein expression were examined by Western Blot. ROS production was measured by dihydroethidium (DHE) staining and thiobarbituric acid reactive substances assay.

RESULTS:

The ratio of Maximum ICP-to-MAP (MaxICP/MAP) was significantly decreased in diabetic ED rats, compared to that of age-matched control rats (P < 0.05). Apocynin improved erectile function of diabetic rats (P < 0.05). Expression levels of RhoA (cytosol), nNOS and eNOS were reduced, compared to those of control rats (P < 0.05). Apocynin significantly elevated their expression levels in diabetic rats (P < 0.05). Expression levels of ROCK1, RhoA (membrane fraction), p-MYPT1 and NADPH oxidase subunits p47(phox) and p67(phox) were increased in diabetic rats when compared to those of control rats (P < 0.05), and it was observed that apocynin significantly reduced their expression levels in diabetic rats (P < 0.05). ROS production was increased in diabetic rats when compared to that of control rats (P < 0.05), the effect of apocynin was a reduction in the ROS production in diabetic rats (P < 0.05).

CONCLUSION:

NADPH oxidase inhibitor apocynin can ameliorate diabetes-related ED by reducing the ROS production and inhibiting the activity of RhoA/ROCK signaling pathway.

Publikation anzeigen